Does BHMT rs3733890 AG reduce betaine-dependent homocysteine clearance when folate and B12 remethylation is strained?

Homocysteine remethylation relies on two parallel pathways: the primary folate- and B12-dependent methionine synthase pathway, and the alternative betaine-dependent betaine-homocysteine methyltransferase (BHMT) pathway.

Mechanistic insights

• Altered Substrate Affinity: The BHMT rs3733890 (R239Q) variant is a functional missense polymorphism that reduces the enzyme's affinity for its substrates, betaine and homocysteine. This modification decreases overall catalytic capacity and limits the maximum rate of alternative clearance.
• Loss of Metabolic Redundancy: Under physiological stress, BHMT serves as an essential redundant buffer. When the primary folate/B12 pathway is strained (due to dietary deficiencies, genetics, or metabolic stressors), reliance on BHMT increases. In rs3733890 AG carriers, this alternative pathway cannot scale up to meet the demand, directly resulting in elevated systemic homocysteine levels.

Clinical implications

• Folate Therapy Resistance: Multiple clinical studies establish that carriers of this mutant allele have a significantly higher risk of folate therapy failure. Because the secondary betaine-dependent clearance pathway is compromised, standard oral folate therapy alone is less effective at lowering elevated homocysteine levels in these individuals.

Bottom line

• The BHMT rs3733890 AG genotype impairs alternative, betaine-dependent homocysteine clearance. When the primary folate and B12 remethylation pathways are strained, this loss of metabolic redundancy limits the body's buffering capacity, leading to elevated homocysteine levels and reduced responsiveness to standard oral folate therapy.